Literature DB >> 9537141

The clinical presentation of children with tumours affecting the anterior visual pathways.

J Suharwardy1, J Elston.   

Abstract

PURPOSE: To review the ways in which children with tumours affecting the anterior visual pathways present and to determine the extent of visual loss at presentation and the visual prognosis after treatment.
METHODS: A retrospective review of the 17 children (age 1-13 years at presentation) referred to a specialist paediatric oncology unit. Ten children had extrinsic tumours affecting the chiasmal area whilst 7 had intrinsic gliomas affecting the optic nerve and/or chiasm. Patients were followed up for up to 13 years (median 2 years).
RESULTS: The children studied presented with a variety of symptoms including headaches, lethargy and growth failure. Despite the clinical finding of marked visual loss in several cases, visual failure was not prominent amongst the presenting symptoms. After surgical intervention and other treatment vision stabilised or improved; eyes with no perception of light for short periods could regain substantial vision.
CONCLUSION: Children with progressive visual deterioration due to tumours do not readily verbalise their difficulty and may have profound loss at presentation. Standard clinical tests of vision will identify the extent of damage. Visual prognosis depends on the underlying pathology and length of history but prompt treatment may lead to substantial improvement in vision.

Entities:  

Mesh:

Year:  1997        PMID: 9537141     DOI: 10.1038/eye.1997.215

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  9 in total

1.  Presentation and symptom interval in children with central nervous system tumors. A single-center experience.

Authors:  Chiara Stocco; Chiara Pilotto; Eva Passone; Agostino Nocerino; Raffaello Tosolini; Anna Pusiol; Paola Cogo
Journal:  Childs Nerv Syst       Date:  2017-08-14       Impact factor: 1.475

2.  Visual electrophysiology in children with tumours affecting the visual pathway. Case reports.

Authors:  J Brecelj; B Stirn-Kranjc; M Skrbec
Journal:  Doc Ophthalmol       Date:  2000-09       Impact factor: 2.379

3.  Delayed diagnosis of childhood low-grade glioma: causes, consequences, and potential solutions.

Authors:  Aska Arnautovic; Catherine Billups; Alberto Broniscer; Amar Gajjar; Frederick Boop; Ibrahim Qaddoumi
Journal:  Childs Nerv Syst       Date:  2015-03-06       Impact factor: 1.475

4.  Giant atypical intraventricular meningioma presenting with visual loss in a child.

Authors:  C Cleary; D Curtin
Journal:  Ir J Med Sci       Date:  2010-07-08       Impact factor: 1.568

5.  Progression from first symptom to diagnosis in childhood brain tumours.

Authors:  Sophie Wilne; Jacqueline Collier; Colin Kennedy; Anna Jenkins; Joanne Grout; Shona Mackie; Karin Koller; Richard Grundy; David Walker
Journal:  Eur J Pediatr       Date:  2011-05-20       Impact factor: 3.183

6.  Predictive factors for vision recovery after optic nerve decompression for chronic compressive neuropathy: systematic review and meta-analysis.

Authors:  Andrew P Carlson; Martina Stippler; Orrin Myers
Journal:  J Neurol Surg B Skull Base       Date:  2012-11-26

7.  Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1.

Authors:  Patrícia de Freitas Dotto; Adriana Berezovsky; Andrea Maria Cappellano; Nasjla Saba da Silva; Paula Yuri Sacai; Frederico Adolfo B Silva; Arthur Gustavo Fernandes; Daniel Martins Rocha; Solange Rios Salomão
Journal:  Doc Ophthalmol       Date:  2018-05-15       Impact factor: 2.379

Review 8.  Optic pathway gliomas: a review.

Authors:  Iris Fried; Uri Tabori; Tarik Tihan; Arun Reginald; Eric Bouffet
Journal:  CNS Oncol       Date:  2013-03

9.  Preoperative Visual Loss is the Main Cause of Irreversible Poor Vision in Children with a Brain Tumor.

Authors:  Nitza Goldenberg-Cohen; Miriam Ehrenberg; Helen Toledano; Liora Kornreich; Moshe Snir; Iftach Yassur; Ian J Cohen; Shalom Michowiz
Journal:  Front Neurol       Date:  2011-09-30       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.